AXSM Q1 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$95M

Gross Profit

$87M92.0% margin

Operating Income

-$6M-6.7% margin

Net Income

-$11M-11.9% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+288.1%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$389M

Total Liabilities

$277M

Stockholders' Equity

$112M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$0	—
Gross Profit	$87M	$0	—
Operating Income	-$6M	-$38M	+83.4%
Net Income	-$11M	-$40M	+71.7%

Revenue Segments

License

$66M70%

Product

$29M30%

Royalty

$272,0000%